JNJ

185.5

-1.47%↓

ABT

124.73

-2.52%↓

MDT

92.01

-2.27%↓

VEEV

288.66

-2.57%↓

144.54

-1.09%↓

JNJ

185.5

-1.47%↓

ABT

124.73

-2.52%↓

MDT

92.01

-2.27%↓

VEEV

288.66

-2.57%↓

144.54

-1.09%↓

JNJ

185.5

-1.47%↓

ABT

124.73

-2.52%↓

MDT

92.01

-2.27%↓

VEEV

288.66

-2.57%↓

144.54

-1.09%↓

JNJ

185.5

-1.47%↓

ABT

124.73

-2.52%↓

MDT

92.01

-2.27%↓

VEEV

288.66

-2.57%↓

144.54

-1.09%↓

JNJ

185.5

-1.47%↓

ABT

124.73

-2.52%↓

MDT

92.01

-2.27%↓

VEEV

288.66

-2.57%↓

144.54

-1.09%↓

Kodu・Aktsiate loetelu・Pulse Biosciences Inc

Pulse Biosciences Inc

Avatud

SektorTervishoid

17.34 -0.34

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.1

Max

17.45

Põhinäitajad
By Trading Economics
Sissetulek	-2.4M -19M
Aktsiakasum	-0.28
Kasumimarginaal	-2,018.63
Töötajad	75
EBITDA	-857K -19M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. nov 2025

Turustatistika
By TradingEconomics
Turukapital	224M 1.2B
Eelmine avamishind	17.68
Eelmine sulgemishind	17.34

Uudiste sentiment

By Acuity

20%

80%

32 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

16.59 / 17.17 Toetus ja vastupanu

Pulse Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. okt 2025, 23:50 UTC

Kuumad aktsiad

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28. okt 2025, 23:25 UTC

Tulu

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28. okt 2025, 23:18 UTC

Tulu

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28. okt 2025, 22:20 UTC

Tulu

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28. okt 2025, 22:13 UTC

Tulu

Wal-Mart de Mexico Net Profit Falls in 3Q

28. okt 2025, 21:38 UTC

Tulu

Correction to Visa Sales Jump Article

28. okt 2025, 21:17 UTC

Tulu

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28. okt 2025, 21:07 UTC

Tulu

Visa Sales Jump as Consumers Keep Spending -- Update

28. okt 2025, 21:02 UTC

Tulu

Mondelez Tempers Outlook as Costs Rise

28. okt 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28. okt 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28. okt 2025, 23:02 UTC

Tulu

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28. okt 2025, 23:01 UTC

Tulu

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28. okt 2025, 22:46 UTC

Tulu

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28. okt 2025, 22:45 UTC

Tulu

SK Hynix 3Q Net KRW12.6T >000660.SE

28. okt 2025, 22:44 UTC

Tulu

SK Hynix 3Q Rev KRW24.44T >000660.SE

28. okt 2025, 22:43 UTC

Tulu

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28. okt 2025, 22:42 UTC

Tulu

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28. okt 2025, 22:40 UTC

Tulu

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28. okt 2025, 22:40 UTC

Tulu

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28. okt 2025, 22:22 UTC

Tulu

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28. okt 2025, 22:20 UTC

Tulu

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28. okt 2025, 22:02 UTC

Tulu

Review & Preview: Earnings Extravaganza -- Barrons.com

28. okt 2025, 21:42 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

28. okt 2025, 21:42 UTC

Market Talk

Tulu

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28. okt 2025, 21:20 UTC

Tulu

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28. okt 2025, 21:19 UTC

Tulu

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28. okt 2025, 21:18 UTC

Tulu

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Võrdlus sarnastega

Hinnamuutus

Pulse Biosciences Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Pulse Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

16.59 / 17.17Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

32 / 373 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.